

Appendix A


Claim Amendments

1. (Currently amended) Pharmacologically A
pharmacologically compatible metal salt of a
pyridin-2-ylmethylsulphanyl-1H-benzimidazole salts of
pyridin-2-ylmethylsulphanyl-1H-benzimidazoles with H^+/K^+ -
ATPase-inhibitory activity, in which at least one positive
charge equivalent of [[the]] a metal ion is counterbalanced
by a hydroxyl ion, and hydrates or a hydrate thereof.

2. (Currently amended) Pharmacologically A
pharmacologically compatible metal salt [[salts]] according
to claim 1, in which the pyridin-2-ylmethyl-
sulphanyl-1H-benzimidazole pyridin-2-ylmethyl-
sulphanyl-1H-benzimidazoles with H^+/K^+ -ATPase-inhibitory
activity is selected from the group consisting of
pantoprazole, omeprazole, lansoprazole, rabeprazole,
tenatoprazole, (R)-pantoprazole, (S)-pantoprazole, (R)-
omeprazole, (S)-omeprazole, (R)-lansoprazole, (S)-lanso-
prazole, (R)-rabeprazole, (S)-rabeprazole, (R)-
tenatoprazole, and tenatoprazole, (R) and (S)

pantoprazole, (R)- and (S)-omeprazole, (R)- and (S)-lansoprazole, (R)- and (S)-rabeprazole and (R)- and (S)-tenatoprazole, and hydrates thereof.

3. (Currently amended) Pharmacologically A
pharmacologically compatible metal salt [[salts]] according
to claim 1, characterized by the general formula 1



in which

Me is a pharmacologically acceptable two-valued metal ion,
PPI is a compound selected from the group consisting of
pantoprazole, omeprazole, lansoprazole, rabeprazole,
[[and]] tenatoprazole and their enantiomers,

OH is a hydroxyl ion,

X is a positive, whole number from 1 to 3,

Y is a positive, whole number from 1 to 5 and

Z is a positive, whole number from 1 to 5,

whereby the equation $(Y + Z) = 2X$ applies, and hydrates or
a hydrate thereof.

4. (Currently amended) Pharmacologically A
pharmacologically compatible metal salt [[salts]] according
to claim 1, characterized by the general formula 1 ~~of claim~~
3,

[Me]_x[PPI]_y[OH]_z (1)

in which

Me is a pharmacologically acceptable two-valued metal ion selected from the group consisting of magnesium, calcium and zinc,

PPI is a compound selected from the group consisting of pantoprazole, omeprazole, lansoprazole, rabeprazole, [[and]] tenatoprazole and their enantiomers,

OH is a hydroxyl ion,

X is the number 1 or 2,

Y is a positive, whole number from 1 to 3 and

Z is a positive, whole number from 1 to 3,

whereby the equation (Y + Z) = 2X applies, ~~and hydrates or~~
a hydrate thereof.

5. (Currently amended) Pharmacologically A
pharmacologically compatible metal salt [[salts]] according

to claim 1, characterized by the general formula 1 of claim

3,

[Me]_x[PPI]_y[OH]_z (1)

in which

Me is magnesium,

PPI is a compound selected from the group consisting of
pantoprazole, (R)-pantoprazole and (S)-pantoprazole,

OH is a hydroxyl ion,

X is the number 1 or 2,

Y is the number 1 or 3 and

Z is the number 1 or 3,

whereby the equation (Y + Z) = 2X applies, and hydrates or
a hydrate thereof.

6. (Currently amended) Pharmacologically A
pharmacologically compatible metal salt [[salts]] according
to claim 1, characterized by the general formula 1 of claim
3,

[Me]_x[PPI]_y[OH]_z (1)

in which

Me is magnesium,

PPI is (S)-pantoprazole,

OH is a hydroxyl ion,

X is the number 1 or 2,

Y is the number 1 or 3 and

Z is the number 1 or 3,

whereby the equation $(Y + Z) = 2X$ applies, ~~and hydrates or~~
a hydrate thereof.

7. (Currently amended) Pharmacologically A
pharmacologically compatible metal salt according to claim
1, which is Mg[Pantoprazole]OH, ~~and hydrates or a hydrate~~
thereof.

8. (Currently amended) Pharmacologically A
pharmacologically compatible metal salt according to claim
1, which is Mg[(S)-Pantoprazole]OH, ~~and hydrates or a~~
hydrate thereof.

9. (Currently amended) Pharmacologically A
pharmacologically compatible metal salt according to claim

1, which is $Mg_2[Pantoprazole]_3OH$, and ~~hydrates or a hydrate~~ thereof.

10. (Currently amended) ~~Pharmacologically A~~
pharmacologically compatible metal salt according to claim 1, which is $Mg_2[(S)-Pantoprazole]_3OH$, and ~~hydrates or a~~ hydrate thereof.

11. - 12. (Canceled)

13. (New) A pharmaceutical composition comprising a pharmacologically compatible metal salt according claim 1 or a hydrate thereof and a pharmaceutically acceptable auxiliary.

14. (New) A method of treating a gastrointestinal disorder in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a pharmacologically compatible metal salt according to claim 1 or a hydrate thereof.